Investor Presentation

INVESTOR PRESENTATION Q1 FY27 Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness,accuracy, completeness or correctness of any information contained herein. This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changesin theIndian andinternational interest rates, change inlaws and regulations thatapplyto theIndian andglobalindustries that we serve, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised tomake their own calculations before deciding onany matter basedon the information given herein. No part of this presentation may be reproduced, quoted orcirculated without prior written approval from Vimta Labs Ltd. Table Of • Q1 FY27 Earnings Contents • Company Overview • Industry Landscape • Our Competitive Advantage • Way Forward Q1 FY27 Earnings Section • Q1 FY27 Highlights • Key Metrics: Q1 FY27 • Profit & Loss Statement • Financial Track Record Q1 FY27 Highlights Rs 411 Rs 1,129 Mn Rs 283 Mn Mn Margin 36.4% Total Income EBITDA PBT Rs 210 Rs 4.7 Rs 180 Mn Margin 18.6% CAPEX (Cash EPS PAT Outflow) Key Metrics: Q1 FY27 Total Income EBIDTA & EBIDTA PAT & PAT Margin Basic EPS (In ₹) (In ₹ Mn) Margin (In ₹ Mn, %) (In ₹ Mn, %) EBIDTA EBIDTA Margin PAT PAT Margin 13.7% 16.0% 11.1% YoY YoY YoY 35.7% 37.6% 19.0% 18.9% 36.4% 18.6% 993 1,120 1,129 354 421 411 189 211 210 4.2 4.7 4.7 Q1FY26 Q4FY26 Q1FY27 Q1FY26 Q4FY26 Q1FY27 Q1FY26 Q4FY26 Q1FY27 Q1FY26 Q4FY26 Q1FY27 Profit & Loss Statement Particulars (₹ Mn) Q1 FY27 Q4 FY26 QoQ(%) Q1 FY26 YoY (%) Revenue from Operations 1,091 1,092 976 Other Income 38 28 17 Total Income 1,129 1,120 0.8% 993 13.7% Material and Testing Costs 226 224 188 Cost of lab setup 0 0 0 Changes in inventories of work-in-progress - - - Employee benefits expense 294 296 278 Other expenses 197 178 172 Total Expenses 718 699 639 Exceptional Item EBIDTA 411 421 -2.4% 354 16.0% EBIDTA (%) 36.4% 37.6% 35.7% Finance costs 2 3 3 Depreciation expense 125 128 99 PBT 283 290 -2.4% 253 12.2% PBT (%) 25.1% 25.9% 25.4% Tax 73 79 64 PAT 210 211 -0.3% 189 11.4% PAT (%) 18.6% 18.9% 19.0% Basic EPS (INR) 4.7 4.7 -0.5% 4.2 11.0% Financial Track Record TOTAL INCOME (₹ Mn) PROFITABILITY (₹ Mn) EBITDA & EBITDA PAT & PAT Margin Margin 19% 10.5% 29% 31% 33% 36% 36% 36% 16.2% 15% 15% 17% 19% 19% 17.0% CAGR CAGR CAGR 2,797 3,216 2,923 3,482 4,163 1,129 (FY22-FY26) 817 984 977 1,262 1,489 411 (FY22-FY26) 413 482 488 668 775 210 (FY22-FY26) FY22 FY23 FY24 FY25 FY26 Q1 FY27 FY22 FY23 FY24 FY25 FY26 Q1 FY27 FY22 FY23 FY24 FY25 FY26 Q1 FY27 Total Revenue EBIDTA EBIDTA Margin PAT PAT Margin BALANCE SHEET RATIOS RoE(%) RoCE(%) Debt to Equity Total Capex 18% 17% 15% 18% 17% 25% 22% 19% 23% 21% 0.08 0.05 0.06 0.02 0.01 450 492 763 791 998 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 1.Financial numbers for the period FY24 & FY25 are from continuing operations and exclude Diagnostic and Pathological services business 2.CAGR for the period FY20-FY26 8 Company Overview Section • Vimta at a Glance • Our Journey • Our Offerings • Geographical Presence • Management Vimta at a Glance Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high-quality, cutting-edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics, small molecules, agro-chemicals, food & beverages, electronics, medical devices, home and personal care products, and environment testing. 42+ Years 1,400+ ~600,000 10 ~100 Of experience in CRTO Dedicated Multi- Sq. Ft. of Ultra- Labs and Offices Successful Regulatory industry Disciplinary Team modern lab spaces across India Audits Our Journey Infrastructure People Investment Capabilities Revenues 2024 ~600,000 ft2 1300+ 492 M Pharma & Biopharma: Discovery & development 3,223 M services; Food; Environment; Electronics Testing Analytical –Pharma, Biopharma & Food; Clinical 2015 400,000+ ft2 1000+ 580 M Research; Preclinical; Clinical Diagnostics; 1,073 M Environment Testing 2006 200,000+ ft2 600+ 992 M Clinical Research; Environment; Analytical Testing – 542 M Food & Pharma 1992 50,000+ ft2 150+ 85 M Environment; Analytical –Food & Pharma; 16 M Toxicology; Material testing; Clinical Research 1984 500 ft2 6 200,000 Minerals & ores; Metals; Rice bran oil testing 156,000 1.Investment & Revenues in INR 2.Investments depicted may have spread across more than the denoted year 11 Our offerings Drug discovery and development services Food, Agri & Environmental Testing Electronics & Electricals Testing 1. Drug discovery and development services Offerings Pharma Analytical Clinical Research Preclinical Research Pharmaceuticals, Biologics, Medical Industry Pharmaceuticals, Biologics, Nutraceuticals, Medical Devices, Animal Health Device, Agrochemical, Speciality Chemicals Accreditations & DCA, USFDA, WHO, EMA, CDSCO, USFDA, WHO, MHRA, Regulatory OECD-GLP, CCSEA, DSIR, AAALAC DRAs of Ukraine, Turkey NPRA, and European DRAs Approvals Wide range of analytical services • E&L studies • Microbiology • BA/BE Studies • Comprehensive in vitro, ex vivo • Stability testing • Immunogenicity and in vivo studies • Method studies • Bioanalytical • ADME, and PK development • Characterization • Clinical Trials (Phase I to • IND enabling packages (genetic • Validations • Bioassays IV) t go ex nic eo ralo l g toy x, s ica ofe lot gy yp , h &a tr om xia cc oo kl io ng ey t, i c • Genotoxic studies). Services impurities • Clinical End Point • Chronic toxicology, reproductive • Elemental analysis Studies toxicology, neurotoxicology, • In vitro studies immunotoxicology, and • Claim Studies carcinogenicity • Physical Characterisation • Biowaiver and alternative to animal studies • Dissolution Testing • Ecotoxicology, environmental fate and metabolism studies 2. Biologics - Contract Research & Development Services Offerings Process Development Product Development Industry Biotech & Biopharma Requirements & Small scale Non GMP (R&D) ICH Guidelines (Q2, Q6B, etc.) Compliant guidelines Process and Product Development –DS & DP o Cell Line Development o Downstream Process Development o Formulation Development • Cell line generation • Protein purification development • Pre-formulation studies • Clone screening and selection • Chromatography optimization • Liquid and lyophilized • Cell bank preparation (MCB/WCB) • Yield and purity improvement formulations Services • Expression optimization o Analytical Development • Stability studies o Upstream Process Development • Method development and • Container-closure • Media and feed optimization validation compatibility • Bioreactor process dev [Showing first 8,000 characters — download PDF for full document]